|Bid||7.08 x 3100|
|Ask||7.39 x 1000|
|Day's Range||7.22 - 7.34|
|52 Week Range||2.02 - 7.84|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.67|
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, Dec. 31, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Red Hat, Inc., LSC.
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / JuanMonteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a class action complaint in the United States District Court for the Northern District of California on behalf of holders of Pacific Biosciences of California, Inc. (“PACB”) (PACB) common stock in connection with the proposed acquisition of PACB by Illumina, Inc. (“Illumina”), announced on November 1, 2018 (the “Complaint”). The Complaint, which alleges violations of the Securities Exchange Act of 1934 against PACB and its Board of Directors (the “Board”), is captioned Wang v. Pacific Biosciences of California, Inc., et al., Case No. 3:18-cv-07450-WHA (N.D. Cal.).
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (“Pacific Biosciences” or the “Company”) (NASDAQ GS: PACB) related to the Company’s entry into an agreement to be acquired by Illumina, Inc. (“Illumina”) (NASDAQ GS: ILMN) in a transaction announced on November 1, 2018 (the “Proposed Transaction”). On November 1, 2018, the Board caused Pacific Biosciences to enter into an agreement and plan of merger (the “Merger Agreement”) with Illumina. Pursuant to the terms of the agreement, shareholders of Pacific Biosciences will receive $8.00 in cash for each share of Pacific Biosciences common stock.
NEW YORK , Dec. 6, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Pacific Biosciences of California stock rose from $2.64 at the close of market on December 29, 2017, to $7.47 at the close of market on November 21, 2018, representing a ~183% year-to-date rise. PACB hit its 52-week high of $7.84 on November 8. On November 1, Pacific Biosciences entered into an agreement with Illumina (ILMN) wherein Illumina agreed to acquire it.
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
Pacific Biosciences of California Inc., (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that an international team of scientists have published the highest quality genome assembly to date of the Aedes aegypti mosquito genome using its Single Molecule, Real-Time (SMRT®) technology. “The high-quality genome assembly and annotation described here will enable major advances in mosquito biology and has already allowed us to carry out a number of experiments that were previously impossible,” the authors write.
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pacific Biosciences of California, Inc. (PACB), a company that offers sequencing systems to help scientists resolve genetically complex problems. PacBio® sequencing systems, including consumables and software, provide a simple and fast end-to-end workflow for SMRT sequencing. On November 1, 2018, the Company announced they had signed an agreement for Illumina to acquire Pacific Biosciences in an all-cash transaction.
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / November 6, 2018 / Big biotech stock buybacks "have destroyed more than $12 billion in value, and generated no positive return in total, at least as a portfolio investment," ...
On November 2, Pacific Biosciences of California (PACB) closed at $7.56, which was 67.63% higher than its previous closing price. On November 1, Illumina (ILMN) released a press release announcing the acquisition of Pacific Biosciences of California for a total consideration of $1.2 billion. According to the press release, Illumina expects to close the deal by mid-2019. The acquisition is expected to strengthen Illumina’s position in the genome sequencing market.
Illumina surprised investors this week by announcing it's buying Pacific Biosciences. Here's how the deal could move the needle for investors.
Stocks that moved substantially or traded heavily on Friday: Apple Inc., down $14.74 to $207.48 The company's revenue forecast disappointed Wall Street and it said it will stop reporting quarterly iPhone ...